Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.49 |
| ▸ | BCHE | P06276 | 7/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729395 | 0.90 | CNR2 (0.48) | CNR2BCHEACHECNR1OPRM1 | |
| Hydrochloric Acid SCHEMBL17416412 | 0.89 | CNR2 (0.47) | CNR2BCHEACHECNR1OPRM1 | |
| SCHEMBL6218923 | 0.86 | CNR2 (0.49) | CNR2BCHEACHEHDAC1HDAC8 | |
| SCHEMBL3731195 | 0.82 | BCHE (0.40) | CNR2BCHEACHEHDAC1CNR1 | |
| SCHEMBL7887152 | 0.81 | CNR2 (0.47) | CNR2BCHEHDAC1HDAC8CNR1 | |
| SCHEMBL3733588 | 0.81 | CNR2 (0.51) | CNR2BCHEACHE | |
| SCHEMBL3746499 | 0.81 | HDAC1 (0.41) | HDAC1HDAC8 | |
| SCHEMBL6243978 | 0.80 | BCHE (0.58) | CNR2BCHEACHECNR1OPRM1 | |
| SCHEMBL6216920 | 0.77 | CNR2 (0.68) | CNR2BCHEACHECNR1OPRM1 | |
| SCHEMBL6221079 | 0.77 | CNR2 (0.48) | CNR2BCHEACHECNR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| WO-2010103306-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIVARAL AGENTS | ASTRAZENECA UK LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | CNR2 2323/4885BCHE 3288/4885ACHE 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.